|Articles|September 10, 2019
FDA Extends CRADA with CluePoints
Advertisement
The Federal Drug Administration has decided to extend the Cooperative Research and Development Agreement with CluePoints until October 2021. The extension will include research focused on real-world evidence and 'moderators of treatment effect'.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
2
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
3
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
4
Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
